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Abstract
Fortunately radiation accidents are infrequent
occurrences, but since they have the potential of
large scale events like the nuclear accidents of
Chernobyl and Fukushima, preparatory planning of
the medical management of radiation accident
victims is very important. Radiation accidents can
result in different types of radiation exposure for
which the diagnostic and therapeutic measures, as
well as the outcomes, differ. The clinical course of
acute radiation syndrome depends on the absorbed
radiation dose and its distribution. Multi-organ-
involvement and multi-organ-failure need be taken
into account. The most vulnerable organ system to
radiation exposure is the hematopoietic system. In
addition to hematopoietic syndrome, radiation
induced damage to the skin plays an important role
in diagnostics and the treatment of radiation accident
victims. The most important therapeutic principles
with special reference to hematopoietic syndrome
and cutaneous radiation syndrome are reviewed.
Introduction
Fortunately, radiation accidents are infrequent occur-
rences, but since they have the potential of resulting in
large scale events, such as the nuclear accidents of
Chernobyl and Fukushima, preparatory planning for
medical management of radiation accident victims is
very important [1].
Radiation accidents can result in radiation exposure to
only a few up to several hundreds of people, depending
on the type of accident and the amount of radiation
exposure. Radiation exposure can occur as external expo-
sure, for instance, from a sealed radiation source, or as
internal exposure due to the intake of radionuclides. In a
nuclear disaster scenario like the Chernobyl accident, a
combination of external and internal radiation exposure
could occur. Radiation exposure can also be categorized
as either chronic or acute, depending on the period of
time of radiation exposure. Another important factor
that can effect treatment and outcome is whether the
whole body of a person was affected homogeneously or if
only localized radiation exposure of a part of the body
occurred.
For each of these different types of scenarios and com-
binations the expected consequences for the patient,
depending on the absorbed radiation dose and distribu-
tion as well as diagnostic and therapeutic measures, are
different. In the case of whole body exposure, all organs
and organ systems are affected and, therefore, multi-
organ-involvement and multi-organ-failure have always
to be taken into account. Additional conventional
trauma, such as wounds and burns in people with severe
radiation exposure - the so-called radiation combined
injury, could worsen the prognosis [2].
There are many aspects to consider when diagnosing
and managing radiation exposed patients. Acute versus
chronic effects can be differentiated by the latency of man-
ifestation of the radiation effects. Since acute effects
require immediate therapeutic intervention, they should
be diagnosed at an early stage. Another differentiation
could be made between deterministic versus stochastic
effects regarding their pathophysiological mechanisms.
Deterministic radiation effects, such as the hematopoietic
syndrome, occur after a threshold radiation dose is
exceeded and the severity will increase with increasing
radiation exposure. For stochastic effects like the develop-
ment of malignant tumors on the other hand, the prob-
ability of their appearance will increase with increasing
radiation exposure.
Therefore, all efforts must be made to reduce the indi-
vidual exposure to ionizing radiation and, thus, the
absorbed dose [3].
The identification of external contamination with
radionuclides is important, since in the case of external
contamination patients have to be decontaminated as
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to protect first responders, medical personnel, facilities
and equipment from contamination. If patients have
incorporated radionuclides, a specific de-corporation
therapy must be carried out as soon as possible to
reduce the resulting radiation dose. Since the de-cor-
poration therapy has to be specific for the involved
radionuclide, the identification of the radionuclide must
be the initial step [1]. Even though guidelines for de-
corporation therapy are available on national and inter-
national levels, some of the substances are not approved
for this purpose in all countries and “off label use”
might be required [4].
For the planning of the medical management of radia-
tion accident victims, it is crucial to estimate the severity
of the radiation exposure on the basis of the individual
patient’s clinical signs and symptoms by means of a clini-
cal dosimetry.
After significant acute whole body or partial body radia-
tion exposure, resulting in acute radiation induced health
impairments, it is imperative that appropriate therapeutic
measures be carried out as soon as possible.
When dealing with specific recommendations for coun-
termeasures against radiation-induced health impairments,
the main fact is that due to the comparatively low number
of radiation victims worldwide, there is a clear lack of con-
trolled studies in this area. Therefore, established and
accepted animal models [5], as well as recommendations
of national and international expert panels and commit-
tees in this field [6-8], are the main sources of information.
Still there remains uncertainty in many areas, which is the
basis for future research. This review, therefore, will
mainly focus on established therapeutic measures in the
clinical management of radiation accident victims suffer-
ing from acute radiation effects.
Acute radiation syndrome (ARS)
Depending on the magnitude of the radiation exposure
resulting in significant whole body exposure or partial
body exposure, the patient will develop clinically acute
radiation effects resulting in acute radiation syndrome
(ARS).
The biological effects of ionizing radiation will start on
the cellular level by energy absorption due to several
physical effects, such as the Compton process and the
photoelectric process for x- or gamma-rays. The most
important targets are the DNA-molecules, where direct
or indirect actions of radiation could result in lesions,
such as base damage, single-strand breaks and double-
strand breaks. Double-strand breaks are considered the
most serious DNA-lesions, since they can result in the
cleavage of chromatin and might not be successfully
repaired by the cell. The occurrence of DNA-lesions
and, especially, of double-strand breaks will increase
with increasing radiation exposure and will lead to a
higher risk of cell death [3].
The classical initial symptoms of acute radiation
syndrome occur during the so-called prodromal phase.
Prodromal symptoms include: anorexia, nausea, vomiting,
diarrhoea, fluid loss, fever, hypotension, headache and
early erythema [3,9]. These prodromal symptoms could, if
the possibility of a radiation exposure is not taken into
account, be misinterpreted as unspecific symptoms of gas-
trointestinal or other infectious diseases. For this reason,
the possibility of radiation-induced health impairments
should always be taken into account, if unspecific symp-
toms cannot be properly explained. The prodromal phase
is followed by the latent phase. In the latent phase, symp-
toms will decrease or even disappear. The length of the
latent phase depends on the magnitude of the radiation
exposure. After a very high radiation exposure it can also
be missing. The latent phase will be followed by the mani-
festation phase. The occurrence and severity of clinical
signs and symptoms will depend on the absorbed radiation
dose. Depending on the absorbed radiation dose, the man-
ifestation takes place in different organ systems as syn-
dromes of the hematopoietic system, the gastrointestinal
system, the skin and the neurovascular system. Hemato-
poietic syndrome will occur at a lower dose than the other
syndromes due to the high radiosensitivity of the hemato-
poietic system. Even in asymptomatic patients effects on
the blood cell counts might be observed. A complete
radiation-induced failure of the hematopoietic system on
the other hand requires an ample homogenous whole
body exposure for all hematopoietic stem cells in the bone
marrow to be irreversibly damaged.
With higher radiation exposure, disturbances of the gas-
trointestinal system, such as destruction of the mucosal
layer can take place. A complete loss of the mucosal layer
will be fatal. Very high radiation exposure can result in
neurologic and cardiovascular breakdown causing death
within a few days. The cutaneous syndrome can occur
together with the other syndromes, but cutaneous radia-
tion injury (CRI) could also be the consequence of exter-
nal exposure to beta-radiation in the absence of other
symptoms of ARS [3,9].
All differentiated cells and stem cell pools of the organ-
ism will be affected from acute homogeneous whole body
radiation exposure resulting in multi-organ involvement
(MOI) and even multi-organ failure (MOF).
Pathophysiological aspects of radiation-induced MOI
include systemic inflammatory response syndrome (SIRS)
and consequences of cell loss due to radiation damage
[10]. Therapeutic efforts are to be taken to stabilize the
homoeostasis and to reconstitute the function of organs
and organ systems. A new strategy would be an early ther-
apeutic intervention in order to prevent MOF already in
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behind this development are still poorly understood [11].
Therapeutic principles in clinical management of
patients with ARS
Clinical management of patients with acute radiation syn-
drome is characterized by dealing with radiation induced
impairments of different organ functions, multi-organ
involvement or even multi-organ failure.
In the early stages of the accident situation, reliable
information about physical dosimetry and results from
biodosimetric methods are not always immediately avail-
able. Therefore, the estimation of radiation effects and the
patient’s prognosis will be based on clinical signs and
symptoms as described in the METREPOL system [12].
Instead of making therapeutic decisions only based on
information about the absorbed radiation dose, the
patient’s clinical status will be categorized into response
categories (RC) 1 to 4. According to the METREPOL sys-
tem, organ specific check lists will be used for the grading
of radiation effects in the four most important organ sys-
tems, such as the neurovascular system (N), the hemato-
poietic system (H), the cutaneous system (C) and the
gastrointestinal system (G). Different levels of the severity
of organ system specific clinical signs and symptoms will
then result in response categories, for example, from H1
to H4 for the hematopoietic system. The organ specific
grading will then lead to a resulting RC for the individual
patient. These response categories describe the degree of
radiation-induced damage but also include prognostic
aspects. The definition of the four response categories are
as follows: RC 1 for mild damage, RC 2 for moderate
damage, RC 3 for severe damage and RC 4 for serious or
fatal damage [12].
As soon as reliable information about the physical dose
or results from biodosimetry is available, the data should
be included in therapeutic decision making and sufficient
medical management. It is the prediction of expected
radiation-induced impairments of organs or organ-systems
that is important for this management.
One of the most critical and most vulnerable organ sys-
tems to radiation exposure is the hematopoietic system,
since the limited life-span of blood cells requires continu-
ous cell divisions of hematopoietic stem cells in the bone
marrow. The impairment of the hematopoiesis will result
in pancytopenia of various degrees with consecutive
increased risk of infection, hemorrhage and anemia.
General medical management consists of barrier nursing
conditions, sufficient and immediate therapy of infections
or even prophylactic administration of antibiotic, and anti-
mycotic and antiviral substances [12-14]. Since renal func-
tion is of great importance for maintaining homoeostasis,
findings concerning the effectiveness of angiotensin-
converting enzyme inhibitors and angiotensin II type 1
receptor antagonists in reducing the incidence and severity
of chronic renal and lung injuries have to be taken into
account [15-17]. A preclinical experimental study regard-
ing the therapeutic intervention in the gastrointestinal
tract showed promising results. Administration of the
somatostatin analog SOM230 significantly increased the
survival rate when started 48 hours after radiation expo-
sure [18]. Other possible radiation countermeasures
include cytokines, growth factors and antioxidants which
are able to scavenge free radicals and modulate cell death
signaling or cell cycle progression [19].
Depending on the severity of the hematopoietic syn-
drome, the main therapeutic principles are replacement
with blood products, such as erythrocyte concentrate, the
administration of cytokines like granulocyte colony-stimu-
lating factor (G-CSF) and granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), and the transplantation
of hematopoetic stem cells (HSCT) [20]. The source of
hematopoietic stem cells for HSCT can be bone marrow,
mobilized peripheral blood-derived stem cells, umbilical
cord blood or the fetal liver [21].
The therapeutic use of hematopoietic factors such as G-
CSF, GM-CSF, erythropoietin (EPO) and thrombopoietin
(TPO) has been described in several cases [22-24]. Since
the number of radiation-exposed patients treated with
hematopoietic factors is limited and randomized con-
trolled clinical trials cannot be performed after radiation
accidents, the main supporting evidence for the effective-
ness of hematopoietic factors in ARS is based on experi-
mental animal studies [20,25,26]. Since experimental
animal studies are of such great importance in the field of
radiation effects, they have to meet certain standards to
allow a comparison of the results [5].
The therapeutic use of hematopoietic factors in radia-
tion accident victims will be considered as “off-label use”.
But if the development of severe neutropenia in a patient
is expected, the administration of G-CSF or GM-CSF in
an early stage is recommended [6,8,14].
If unrecoverable damage to the hematopoietic stem cell
pool is noticed, a decision about the necessity of HSCT
has to be made. The diagnosis, whether or not an autolo-
gous recovery of the hematopoiesis could be expected,
requires specific expertise [7,21,27,28]. The experience
from the treatment of patients after several radiation acci-
dents with HSCT showed that the range between the ben-
eficial treatment with HSCT and a very poor prognosis
irrespective of whether HSCT is performed or not, is quite
narrow, especially if other organ systems are severely
affected or MOI already occurred [21,29,30]. HSCT will,
therefore, not be considered as the most important treat-
ment option in ARS, although it could be essential for an
individual patient.
In addition to hematopoetic syndrome, radiation-
induced damage to the skin plays an important role in
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the case of local radiation injuries. The impairment of
the skin could be a real challenge in the clinical manage-
ment of patients with cutaneous radiation syndrome. The
barrier function of the skin will be affected and inflam-
matory reactions will take place, which eventually might
trigger the development of MOF [31,32]. Therapeutic
principles in the clinical management of patients with
cutaneous radiation syndrome include conservative
methods, surgical treatment and the administration of
anti-inflammatory agents and topical steroids [8]. Sys-
temic administration of steroids could be considered for
MOF-related skin dysfunction [23,33]. A novel therapeu-
tic approach is the parenteral or local administration of
mesenchymal stem cells [34]. The treatment of a patient
with a local radiation injury using local cellular therapy
with autologous expanded mesenchymal stem cells to
promote tissue regeneration resulted in favorable pain
relief and healing progression [35]. As conservative meth-
ods, therapeutic measures for pain control, reduction of
inflammation, prevention of infection and of further vas-
culature insult, improvement of circulation, healing
acceleration, wound cleaning and minimizing fibrosis will
be performed. Surgical treatment and skin grafts might
be required if necrosis of various extents occur [32,36].
In order to avoid disturbances of wound healing after
exposure to ionizing radiation, all surgical measures
within the ARS should be performed as soon as possible
[37]. New approaches, such as mesenchymal stem cell
administration derived from experimental studies in ani-
mal models, should be considered in patients with cuta-
neous radiation syndrome [38-42].
Summary and future directions
The development of acute radiation effects in radiation
accident victims depends on the nature and the extent of
radiation exposure. Since reliable information about the
radiation exposure from physical dosimetry and results
from biodosimetric methods are usually not available in
accident situations, the estimation of radiation effects can
be performed on the basis of clinical signs and symptoms
as described in the METREPOL system.
Multi-organ involvement, systemic inflammatory
response syndrome and even multi-organ failure have to
be considered in the clinical management of radiation
accident victims.
Since the hematopoietic system is most vulnerable to
ionizing radiation, diagnostic and therapeutic measures
dealing with the hematopoietic syndrome are most
important. General measures are barrier nursing condi-
tions, sufficient and immediate therapy of infections, or
even prophylactic administration of antibiotic, antimyco-
tic and antiviral substances. The main specific therapeu-
tic principles are replacement with blood products, the
administration of cytokines like G-CSF and GM-CSF,
and the transplantation of hematopoietic stem cells.
In addition to hematopoietic syndrome, radiation-
induced damage to the skin plays an important role in
diagnostics and treatment of patients with ARS and
eventually might trigger the development of multi-organ
failure.
New approaches are based on the administration of
stem cells, such as mesenchymal stem cells, in the case
of cutaneous radiation syndrome and localized radiation
injuries. Since radiation-induced multi-organ involve-
ment or multi-organ failure will be associated with a
poor prognosis in the patient, early therapeutic interven-
tion for preventing the development of MOI and MOF
seems to be one of the most important aspects for
further research.
Conclusions
From past experiences, we know that radiation accidents
fortunately are rare events; therefore, the number of
patients suffering from acute radiation effects and ARS
is limited. However, current risk analyses of terrorist
threats consider a nuclear scenario as extremely rele-
vant. This certainly would mean that the number of vic-
tims would be in a much higher magnitude. Availability
of necessary resources could be a limiting factor for the
medical management of radiation accident victims.
Stockpiling of essential pharmaceuticals for the treat-
ment of radiation accident victims on a national or
international level has to be considered.
Prospective studies for the development of therapeutic
standards for patients with ARS are extremely limited.
Most of the new approaches in therapeutic measures
are derived from experimental studies in animal models.
Keeping these circumstances in mind, a multidisciplin-
ary approach built on international cooperation is of the
utmost importance and currently the most reasonable
strategy to provide the best possible medical care for
radiation accident victims. The clinical course, as well as
the therapeutic regimen, of each new radiation accident
victim should be documented in detail for further analy-
sis, as in the SEARCH database [43].
There is a strong need for internationally recognized
guidelines for the treatment of severely radiation-
exposed patients [8]. Further research and experimental
studies are necessary to identify prognostic parameters
for the estimation of irreversible damage to organs and
organ systems and a deeper understanding of the patho-
physiology of radiation induced MOF.
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